Tiragolumab Placebo clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, tiragolumab, combined with an existing cancer drug, atezolizumab (Tecentriq), for people with a type of lung cancer called non-small cell lung cancer that hasn't been treated with chemotherapy yet. It aims to see how well this combination works.
For: Non-small cell lung cancer (NSCLC)Spain · France - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer
This study looks at new drug combinations for advanced non-small cell lung cancer. It compares two treatments, one with a new drug called tiragolumab, to see which works best at shrinking tumours, stopping cancer growth, and helping people live longer and have a better quality of life.
For: Non-squamous non-small cell lung cancer (NSCLC)Spain · France · Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Randomized, Double-Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
This study looks at new treatments for a type of head and neck cancer. It compares two drug combinations to see if they help shrink tumors and improve how long people live, while also checking for side effects.
For: Squamous cell carcinoma of the head and neck (SCCHN)Greece · France · Poland